Evaluation of children with endocrine and metabolic conditions
Official title: Evaluation of Children With Endocrine and Metabolic-Related Conditions
Run by National Institutes of Health Clinical Center (CC) · NCT02769975 · Data updated 2026-11-12
This study is testing how endocrine and metabolic disorders affect children from 3 months to 18 years old by looking at their medical history and physical exams, and it may involve family members in genetic testing to help with diagnosis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 3 Months to 100 Years |
| Sex | All |
| Enrollment | 15000 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | July 12, 2016 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | October 21, 2026 |
| Trial ID | NCT02769975 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include children aged 3 months to 18 years with known or suspected endocrine or metabolic disorders.
✕Probably not a fit
Patients without suspected endocrine disorders or those with severe medical conditions that could complicate participation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate children aged 3 months to 18 years who have known or suspected endocrine or metabolic disorders. Researchers will conduct comprehensive assessments, including medical history reviews and physical exams, to understand the inheritance and progression of these conditions. Family members may also participate in genetic testing to aid in diagnosis. The study will track the natural development of these disorders in a diverse pediatric population.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and treatment options for children with endocrine and metabolic disorders.
How similar studies have gone: Other studies focusing on genetic and endocrine evaluations in pediatric populations have shown promise, indicating that this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Participants with known or suspected endocrine disorder age 3 months-18 years are eligible for this protocol. * Relatives ages 3 months-100 years may be enrolled if clinically indicated for the diagnosis of a proband. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Lack of suspected endocrine disorders. * Any medical, physical, psychiatric, or social conditions, which, in the opinion of the investigators, would make participation in this protocol not in the best interest of the patient, will exclude participation. Patients who are critically ill, unstable, or with severe organ failure that may affect/limit the endocrine evaluation and place unsustainable demands on Clinical Center or NICHD resources will be excluded.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Catherine M Gordon, M.D. — Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Study coordinator: Harinder D Raipuria, C.R.N.P.
- Email: harinder.raipuria@nih.gov
- Phone: (301) 254-2982
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adrenal Function in RA Patients on Low-Dose Corticosteroids
This study tests how common adrenal insufficiency is among rheumatoid arthritis patients who are taking low-dose corticosteroids.
-
Myokines in metabolic and endocrine diseases linked to sarcopenia
This study tests whether myokines can serve as biomarkers or drivers of sarcopenia and sarcopenic obesity in people with metabolic or endocrine diseases.
-
CTX310 for refractory high triglycerides or LDL cholesterol
This trial will test whether a single IV dose of CTX310 is safe and tolerated in adults whose high triglycerides or LDL cholesterol have not responded to available treatments.
-
Safety and tolerability of SNS851 in healthy adults.
This study will test whether a new injectable drug called SNS851 is safe and well-tolerated when given under the skin to healthy adults aged 18 to 55.
-
Linoleic acid–rich oil versus blended oil for adults with insulin resistance
This trial will test whether taking a linoleic acid–rich oil daily for 8 weeks improves insulin resistance in adults who already have insulin resistance.
-
Normal ranges and diagnostic cut-offs for salivary cortisol
This project will test two saliva cortisol methods — a lab LC‑MS assay and a rapid fluorescence immunoassay — to find normal ranges and the best diagnostic cut-offs for adults with suspected Cushing syndrome or adrenal insufficiency.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.